drugset / Trial / NCT04040023

Patient Blood Management in Cardiac Surgery

NCT04040023

Completed 900 enrolled Clinique Pasteur
Non-randomizedSequentialOpen-labelPrevention

Summary

Preoperative anemia is associated with an important increase in transfusions of red blood cells (RBC) compared to a non-anemic patient in cardiac and non cardiac surgery. Furthermore transfusion is also an independent factor of morbi-mortality with notably an increase in the infectious risk, immunological, an increase of the risk of cardiac decompensation, respiratory decompensation Transfusion Related Acute Lung Injury (TRALI) or Transfusion Associated Cardiac Overload (TACO), and an increase in mortality of 16%. Management of perioperative transfusion is therefore a public health issue. Since 2010, the World Health Organization (WHO) has been promoting a systematic approach to implement blood management programs for the patient to optimize the use of resources and promote quality and safety of care. Improving the relevance of transfusion in cardiac surgery could be achieved by optimizing the management of patients around 2 axis: A:non-drug intervention : Review of Practices to Improve the Management of Perioperative RBC Transfusion B:drug intervention : Systematic correction of pre- and postoperative iron, vitamin deficiencies and anemia The aim of this program is to improve the relevance of transfusion in cardiac surgery and to limit the morbidity and mortality induced by transfusion. This program is part of a global project of pre, per and postoperative management of the patient undergoing cardiac surgery programmed under extracorporeal circulation (ECC). It requires a multidisciplinary approach between cardiologists, anesthesiologists and intensivists, perfusionists, cardiac surgeons and paramedical teams to optimize the management of the patient.

Timeline

Start
2019-09-10
Primary completion
2021-07-24
Completion
2021-09-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Erythropoietin-α Unknown 600 iu/kg
Subject Ferric carboxymaltose Other / unclassified 300 mg Intravenous
Subject Ferric carboxymaltose Other / unclassified 1000 mg Intravenous

Indications

No indication recorded.